IntraPace Names Bart Bandy Chief Commercial Officer

Role will Oversee Continued Commercialization of abiliti System for Obesity

MOUNTAIN VIEW, Calif--()--IntraPace, Inc. announced the appointment of Bart Bandy as its Chief Commercial Officer today. In this role, Mr. Bandy will oversee marketing, business development, and commercialization of the company’s products. Mr. Bandy joins IntraPace at a pivotal point, as the company launches its abiliti® system in Europe. The company announced on March 30th that the first commercial patients in Europe had successfully received the abiliti system as a treatment for obesity.

“I am delighted to be joining the IntraPace team and excited about introducing the innovative and patient friendly abiliti system to the weight loss market. With the system’s advanced behavior monitoring and support programs, it is the most comprehensive obesity intervention available today,” commented Mr. Bandy.

Mr. Bandy has more than 20 years of U.S. and international medical device experience within the bariatric surgery and general surgery marketplaces. Prior to joining IntraPace, he was the Senior Vice President at Inamed/Allergan Health. Mr. Bandy guided the launch of the company’s obesity treatment products, achieving sales of over $250 million, and helped lead the company’s transition following Inamed’s $3.2 billion acquisition by Allergan.

In addition to his time at Inamed, Mr. Bandy also held key positions in sales, marketing and general management with Ethicon Endo-Surgery, Karl Storz, and USGI Medical. Bandy holds a Business Administration degree from California State University, Sacramento. He has also completed executive business programs at the University of California, Los Angeles (UCLA) and the University of Southern California (USC).

Chuck Brynelsen, CEO of IntraPace, said, "The entire IntraPace team is pleased to have an executive of Bart’s caliber leading our commercial efforts. With his extensive knowledge of obesity interventions and his relationships within the bariatric community, he is the perfect choice to build and lead an international team to introduce the abiliti system. We look forward to his contributions as we continue our pursuit of making a positive impact on the global obesity problem.”

About the abiliti System

Following implantation via a simple minimally invasive surgical procedure, the abiliti system detects when a person eats or drinks and sends low level electrical impulses to the stomach. This stimulation is intended to help a person feel full before the stomach is actually full, causing them to eat less. As the anatomy of the stomach is not changed, clinical experience with the abiliti system has shown virtually none of the nausea and other side effects seen with gastric bypass surgery and gastric banding. Patients are not restricted in the types of food that they consume, but are encouraged to adopt a healthy diet and exercise program.

Further, this novel system automatically records when a patient eats, drinks and exercises. Using a simple wireless connection, patients and physicians can view the consumption and exercise data. Access to this important information provides an enormous benefit as it allows physicians and patients to understand patient behaviors and develop effective strategies for weight loss. Additionally, the system connects patients to a valuable social support network, support which research has demonstrated increases the effectiveness of weight loss programs.

About IntraPace

IntraPace was founded in 2001 to address an unmet need in weight loss surgery by developing a gentler solution for weight loss that incorporates essential components of behavior therapy. The abiliti system is intended to enable patients to achieve and sustain significant weight loss without the complications, lifestyle restrictions and substantial anatomical changes associated with the established weight loss surgeries.

Based in Mountain View, California, IntraPace is backed by premier investors, including Boston Scientific, CB Health Ventures, DFJ ePlanet Ventures, InCube Ventures, Johnson & Johnson Development Corp., L Capital Partners, Oxford Bioscience Partners, Toucan Capital Corp and Vulcan Capital.

The abiliti system has CE Mark in the European Union. It is not approved for sale in the United States. For more information, visit www.abiliti.com.

Contacts

IntraPace
Chuck Brynelsen, CEO
Tel: +1 (650) 316 4070
or
Sandy Greensmith
Tel: +41 (0)79 665 0486
or
Halsin Partners
Mike Sinclair
Tel: +44 (0)20 7318 2959
msinclair@halsin.com

Release Summary

IntraPace has appointed Bart Bandy as Chief Commercial Officer. He will spearhead continued commercialization of the abiliti system for obesity. Abiliti is a gastric pacemaker.

Contacts

IntraPace
Chuck Brynelsen, CEO
Tel: +1 (650) 316 4070
or
Sandy Greensmith
Tel: +41 (0)79 665 0486
or
Halsin Partners
Mike Sinclair
Tel: +44 (0)20 7318 2959
msinclair@halsin.com